This study is being done to evaluate the safety and efficacy of atrasentan in men with non-metastatic hormone-refractory prostate cancer.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
941
Time-to-disease progression will be determined by the time to onset of the earliest of one of the following events: New skeletal lesions, new metastatic extra-skeletal lesions, or an event due to metastatic prostate cancer.
Time frame: Every 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Urology Centers Of Alabama
Homewood, Alabama, United States
Alaska Clinical Research Center, LLC
Anchorage, Alaska, United States
Advanced Clinical Trials
Tucson, Arizona, United States
Arkansas Urologial Associates, PA
Little Rock, Arkansas, United States
Robin V. Smith, MD
Chula Vista, California, United States
Urology Associate Of Central California
Fresno, California, United States
South Valley Medical Plaza
Gilroy, California, United States
San Diego Urology Center
La Mesa, California, United States
South Orange County Medical Research Center
Laguna Hills, California, United States
UCLA School of Medicine
Los Angeles, California, United States
...and 224 more locations